177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Data From the Prospective Phase 2 LUMEN Study.

Auteurs

Mileva M, Van Bogaert C, Marin G, Danieli R, Artigas C, Levillain H, Ameye L, Taraji-Schiltz L, Stathopoulos K, Wimana Z, Hendlisz A, Flamen P, Karfis I

  • Date de publication

    Juni 2024

  • Type

    Article

  • Tijdschrift

    Clin Nucl Med

  • Naam van de onderzoeker

    ARTIGAS GUIX CARLOS

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Médecine nucléaire IJB

  • PMID

    38914016

  • DOI

    10.1097/RLU.0000000000005330